Cargando…
Loading, please waitCargando…
Loading, please waitConditions
Long COVID (PASC) is a real, multisystem, and debilitating condition. At Regeneris we combine conventional medical management with investigational mesenchymal stem cell protocols as adjuncts, always inside an honest integrative plan.
Long COVID, formally known as post-acute sequelae of SARS-CoV-2 infection or PASC, is a multisystem syndrome that persists for at least twelve weeks after acute SARS-CoV-2 infection and is not explained by an alternative diagnosis. It carries the ICD-10 code U09.9, recognized by the World Health Organization since 2021 to specifically identify this entity.
Current estimates suggest that between 10 and 20 percent of people who contracted COVID-19 develop persistent symptoms of variable duration, even after mild infections that never required hospitalization. A significant subgroup continues to experience disabling manifestations a year or more later, with profound impact on work capacity, family relationships, and quality of life.
The main pathophysiological hypotheses that research has consolidated through 2026 include viral persistence or viral fragments in sanctuary tissues, immune dysregulation with chronic low-grade inflammation, secondary autoimmunity mediated by molecular mimicry, persistent microclotting, mitochondrial dysfunction, diffuse endothelial damage, and autonomic nervous system alterations. These mechanisms coexist in different proportions across patients.
Diagnosis is established clinically: compatible symptoms persisting at least twelve weeks after a documented or presumed SARS-CoV-2 infection, without another medical explanation. There is no single confirmatory biomarker. Evaluation requires a detailed history, physical examination, and targeted studies to rule out other treatable causes (anemia, hypothyroidism, nutritional deficiencies, structural cardiac disease, sleep apnea, major depression).
At Regeneris Therapy we approach long COVID through an integrative protocol. We do not promise a cure — because no established curative intervention exists today — but we do work on modifiable mechanisms: systemic inflammation, mitochondrial function, autonomic balance, sleep, and documented nutritional deficits. Mesenchymal stem cell therapy is considered only as an investigational adjunct, with clear expectations and structured follow-up.
Long COVID has no single cause. Research through 2026 points to five main mechanisms that coexist in varying proportions in each patient: viral persistence, immune dysregulation, chronic microcoagulation, mitochondrial dysfunction, and autonomic nervous system disruption. Understanding which predominates in a particular case guides the therapeutic approach.
Viral persistence: studies have identified remnants of the virus or its RNA in tissues such as the gut, lymph nodes, and nervous system months after acute infection. These viral reservoirs may sustain chronic low-grade immune activation, perpetuating inflammatory and fatigue symptoms.
Immune dysregulation: many patients show persistent elevation of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-17), reduction of regulatory T cells, and the appearance of autoantibodies against adrenergic, muscarinic, and angiotensin receptors. This profile suggests secondary autoimmunity, likely triggered by molecular mimicry between viral proteins and host tissues.
Microcoagulation and endothelial damage: SARS-CoV-2 directly infects endothelial cells via the ACE2 receptor. Persistent microclots resistant to normal fibrinolysis have been documented in long COVID patients, along with widespread endothelial dysfunction that impairs tissue perfusion and contributes to fatigue, brain fog, and POTS.
Mitochondrial dysfunction: direct viral damage and chronic inflammation impair mitochondrial function in multiple tissues, compromising ATP production. This explains exercise intolerance, profound fatigue, and the characteristic post-exertional malaise, a phenomenon also described in myalgic encephalomyelitis/chronic fatigue syndrome.
Dysautonomia: the autonomic nervous system, which regulates blood pressure, heart rate, digestion, and temperature, becomes dysregulated in many patients. Post-COVID POTS is a common and recognized manifestation; it reflects a failure of cardiovascular adaptation to orthostasis and often responds to specific interventions (hydration, electrolytes, compression, low-dose beta-blockade, ivabradine).
Identified risk factors include: severe acute infection (although it also occurs after mild cases), female sex, middle age (35-55), prior comorbidities such as asthma, obesity, or diabetes, history of migraine or prior dysautonomia, and reactivation of latent viruses (especially Epstein-Barr) during or after the acute infection.
If managing long COVID has taught us anything, it's that no single treatment resolves a syndrome with so many simultaneous dimensions. The internationally recognized standard of care is multidisciplinary and symptomatic: cardiologist or internist for dysautonomia, pulmonologist for persistent dyspnea, neurologist for significant brain fog, physiatrist or therapist for graded rehabilitation, and attention to sleep and mental health. Regenerative medicine adds to this framework, not replaces it.
Mesenchymal stem cell (MSC) therapy has a coherent biological rationale for long COVID. MSCs exert documented immunomodulatory effects: they can reduce pro-inflammatory cytokines (IL-6, TNF-alpha, IL-17), promote regulatory T cell differentiation, dampen the type-I interferon signature, support post-viral endothelial repair, and potentially transfer functional mitochondria to damaged cells via tunneling nanotubes and extracellular vesicles. Each of these mechanisms aligns with a pathophysiological axis identified in PASC.
Clinical evidence through 2026 is promising but preliminary. Chinese groups have led in number of patients treated, with several phase II studies reporting improvements in fatigue, residual pulmonary function, and quality of life after infusions of allogeneic umbilical cord-derived MSCs. European groups in Spain and Italy have published smaller series with stricter methodology, including some controlled trials showing positive signals in brain fog and exercise tolerance. The heterogeneity of protocols (dose, number of infusions, cell source) and modest sample sizes preclude considering this a standard of care for now.
Our protocols use allogeneic umbilical cord-derived MSCs, traceable in accordance with applicable COFEPRIS regulations, processed in licensed Mexican laboratories, and administered intravenously. In selected cases, we complement with intranasal MSC-derived exosomes targeted at neuroinflammatory modulation — a route being actively investigated for neurological components of PASC. Every intervention is documented and discussed with clear expectations: the goal is meaningful symptom improvement, not cure.
IV micronutrient therapy (vitamin C, B-complex, magnesium, glutathione, NAD+ precursors, coenzyme Q10) is used to support mitochondrial function and antioxidant status. Dysautonomia management requires specific interventions: structured hydration (2-3 L/day with salt), electrolytes, compression stockings, evaluation for medications such as low-dose beta-blockade or ivabradine, coordinated with your cardiologist. Brain fog is addressed with cognitive rehabilitation, sleep optimization, and attention to gut microbiota.
A critical point: long COVID management must respect the principle of graded activity, not push. Aggressive exercise protocols can trigger severe post-exertional malaise and worsen the condition. Rehabilitation is designed around individual thresholds, with very conservative progression rates and 24-72 hour response monitoring. Any clinic that recommends an intense protocol without evaluating exercise tolerance is ignoring a basic safety principle in PASC.
Linked protocols
IV infusion of allogeneic MSCs as an investigational immunomodulatory adjunct in selected patients.
MSC-derived extracellular vesicles for neuroinflammatory modulation, evaluated case by case.
Protocols with vitamin C, B-complex, glutathione, NAD+ precursors, and CoQ10 for fatigue and cellular function.
Full medical review of 2026 evidence for stem cells in long COVID.
Explore regenerative medicine
See the full landscape of treatments we offer in Cancún and the science behind each one.
Long COVID has a heterogeneous prognosis. Some patients improve spontaneously within the first six to twelve months; others remain symptomatic for years. Factors associated with better prognosis include younger age, absence of prior comorbidities, less severe acute infection, and early therapeutic approach that does not provoke overexertion.
Patients who respond well to an integrative protocol with MSCs typically describe gradual improvement in baseline energy, reduced frequency and severity of post-exertional malaise, better concentration, and partial recovery of functional capacity. Improvement is rarely sudden or complete; it is typically progressive over weeks to months, and can continue during structured follow-up.
A subgroup of patients does not respond meaningfully. This is consistent with the published literature and the reality that no therapy works for everyone. We discuss this possibility openly during initial evaluation. Setting realistic expectations is not a commercial inconvenience — it is central to responsible care. An MSC infusion will not turn a patient with three years of severe PASC into someone symptom-free in six weeks.
Structured follow-up is part of the protocol. We use validated scales (FACIT fatigue scale, quality-of-life questionnaires, inflammatory markers) at defined intervals to evaluate objective response. When a patient is not improving as anticipated, the plan is reevaluated rather than repeated unchanged. This clinical discipline is what distinguishes responsible investigational therapy from packaged treatments without follow-through.
No. Mesenchymal stem cell therapy is not a proven cure for long COVID. It is an intervention with a rational biological basis and encouraging preliminary clinical evidence, offered as an investigational adjunct within an integrative protocol. Any clinic that promises a cure or guaranteed outcomes is crossing the line between evidence-based medicine and selling hope. We will tell you honestly what we know and what we still don't.
Revisado por Dra. Claudia Labastida · 2026-05-27
Patients who fit best have symptoms persisting at least six months, a prior medical evaluation ruling out other treatable causes, predominance of inflammatory or autonomic symptoms (fatigue, brain fog, POTS), absence of active cancer or uncontrolled infections, and realistic expectations. We perform an honest case-by-case evaluation and respectfully redirect when a regenerative adjunct is not the right option.
Revisado por Dra. Claudia Labastida · 2026-05-27
Clinical response, when it occurs, is usually gradual over weeks to months. Some patients report subtle changes in energy and sleep within the first 2-4 weeks, with clearer improvements in fatigue and cognitive function between the second and fourth month. Improvement can continue throughout the follow-up period. Don't expect a sudden transformation; that is not what the biology of MSCs predicts.
Revisado por Dra. Claudia Labastida · 2026-05-27
Published protocols vary: some use a single infusion, others apply 2-3 infusions spaced monthly. The choice depends on clinical profile, symptom severity, and initial response. We do not commercially prescribe a fixed number of infusions; we adjust based on clinical response evaluated with validated scales. If a first infusion produces no signs of improvement, rethinking the protocol is more honest than repeating it automatically.
Revisado por Dra. Claudia Labastida · 2026-05-27
Exosomes are extracellular vesicles secreted by MSCs that contain many of the signaling molecules responsible for therapeutic effect (proteins, RNAs, lipids), but without the whole cells. They have theoretical advantages: smaller size, ability to cross barriers like the blood-brain barrier (useful for neurological components of PASC), and a potentially cleaner safety profile. PASC-specific clinical evidence is earlier than for whole MSCs, but it is an active area of research.
Revisado por Dra. Claudia Labastida · 2026-05-27
Yes, always. Regenerative medicine at Regeneris is offered as an adjunct, not a replacement. If you are under follow-up with a cardiologist for POTS, a neurologist for severe brain fog, or a psychiatrist for neuropsychiatric components, you must continue that treatment. We coordinate with your treating physicians and share documentation when relevant for your integrated care.
Revisado por Dra. Claudia Labastida · 2026-05-27
The safety profile of allogeneic umbilical cord-derived MSCs applied IV is reasonably favorable in published studies. The most common adverse events are mild infusion reactions (transient fever, chills, headache), generally self-limited. Theoretical risks include immunological reactions and, in patients with risk factors, thromboembolic events. Our pre-treatment evaluation rules out contraindications, and we monitor during and after infusion.
Revisado por Dra. Claudia Labastida · 2026-05-27
Costs vary based on the initial evaluation required, the number of MSC infusions indicated, whether exosomes are included, and the supportive IV therapy protocols. We provide a transparent quote before starting, with no surprise charges, and discuss options according to budget. We see local and international patients and can coordinate logistics for those traveling from outside Cancún.
Revisado por Dra. Claudia Labastida · 2026-05-27
An honest medical review of mesenchymal stem cell therapy for long COVID (PASC): anti-inflammatory mechanisms, clinical evidence, and integrative protocol.
An evidence-based overview of current research into mesenchymal stem cells and exosomes for autoimmune diseases, including lupus, rheumatoid arthritis, and multiple sclerosis.
A clear explanation of what exosomes are, how they differ from stem cells, and why they are often discussed together in regenerative medicine.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisLumbar disc herniation (ICD-10 M51.2) occurs when the nucleus pulposus of an intervertebral disc displaces through the annulus fibrosus and compresses neighboring nerve structures. At Regeneris Therapy we combine an honest evaluation, recent imaging and mesenchymal stem cell therapy as a middle path between failed conservative care and surgery — for patients who meet clear clinical criteria.
Learn about Lumbar Disc HerniationFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsNext step
If you've spent months with persistent symptoms after COVID-19 and feel conventional management has plateaued, we're here to listen. We block enough time to understand your full story, review your studies, and design a plan that combines integrative medical care with regenerative options when appropriate — and a "not for you right now" when that's the right answer.